MA24747A1 - Composition de mesylate de trovafloxacine et procede pour sa preparation - Google Patents

Composition de mesylate de trovafloxacine et procede pour sa preparation

Info

Publication number
MA24747A1
MA24747A1 MA25433A MA25433A MA24747A1 MA 24747 A1 MA24747 A1 MA 24747A1 MA 25433 A MA25433 A MA 25433A MA 25433 A MA25433 A MA 25433A MA 24747 A1 MA24747 A1 MA 24747A1
Authority
MA
Morocco
Prior art keywords
preparation
trovafloxacin mesylate
mesylate composition
composition
trovafloxacin
Prior art date
Application number
MA25433A
Other languages
English (en)
Inventor
Dale Johnson Alton
Michael Sinko Christopher
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA24747A1 publication Critical patent/MA24747A1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA25433A 1998-01-21 1999-01-15 Composition de mesylate de trovafloxacine et procede pour sa preparation MA24747A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7201398P 1998-01-21 1998-01-21

Publications (1)

Publication Number Publication Date
MA24747A1 true MA24747A1 (fr) 1999-10-01

Family

ID=22105016

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25433A MA24747A1 (fr) 1998-01-21 1999-01-15 Composition de mesylate de trovafloxacine et procede pour sa preparation

Country Status (34)

Country Link
US (1) US6187341B1 (fr)
EP (1) EP0930068A3 (fr)
JP (1) JPH11269072A (fr)
KR (1) KR100314977B1 (fr)
CN (1) CN1227743A (fr)
AP (1) AP1094A (fr)
AR (1) AR012780A1 (fr)
AU (1) AU758381B2 (fr)
BG (1) BG103106A (fr)
BR (1) BR9900116A (fr)
CA (1) CA2259698C (fr)
CO (1) CO4810225A1 (fr)
DZ (1) DZ2712A1 (fr)
EA (1) EA003247B1 (fr)
GT (1) GT199900004A (fr)
HR (1) HRP990023A2 (fr)
HU (1) HUP9900154A3 (fr)
ID (1) ID23735A (fr)
IL (1) IL128051A0 (fr)
IS (1) IS4947A (fr)
MA (1) MA24747A1 (fr)
NO (1) NO990243L (fr)
NZ (1) NZ333838A (fr)
OA (1) OA10958A (fr)
PA (1) PA8466701A1 (fr)
PE (1) PE20000169A1 (fr)
PL (1) PL330981A1 (fr)
SG (1) SG70666A1 (fr)
SK (1) SK4299A3 (fr)
TN (1) TNSN99007A1 (fr)
TR (1) TR199900089A2 (fr)
TW (1) TW518224B (fr)
YU (1) YU2399A (fr)
ZA (1) ZA99393B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100650489B1 (ko) * 1998-11-10 2006-11-28 바이엘 헬스케어 아게 목시플록사신 제약 제제
AU1188601A (en) * 1999-09-20 2001-04-24 Alza Corporation Process for lessening polymorphic conversion of a drug
PE20010635A1 (es) * 1999-10-08 2001-08-15 Smithkline Beecham Corp Inhibidores de fab i utiles para el tratamiento de infecciones bacterianas
FR2808441B1 (fr) * 2000-05-04 2004-06-18 Oreal Utilisation de fibres dans une composition de soin ou de maquillage pour matifier la peau
DE10031043A1 (de) * 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
ES2320984T3 (es) * 2001-04-06 2009-06-01 Affinium Pharmaceuticals, Inc. Inhibidores de fab i.
EP1396263A1 (fr) * 2002-08-09 2004-03-10 Warner-Lambert Company Compositions d'enrobage pour tablettes et caplets
ES2518316T3 (es) 2002-12-06 2014-11-05 Debiopharm International Sa Compuestos heterocíclicos, métodos de fabricación de los mismos y su uso en terapia
CN100415284C (zh) * 2002-12-30 2008-09-03 毛友昌 六味木香片的制备方法
CA2519429C (fr) 2003-03-17 2013-08-06 Affinium Pharmaceuticals, Inc. Compositions pharmaceutiques comportant des inhibiteurs de fab i et autres antibiotiques
DE60318384T2 (de) * 2003-03-19 2009-02-19 The Jordanian Pharmaceutical Manufacturing Co. Ltd. Nicht-hygroskopische pharmazeutische Zusammensetzungen die nicht hydratisierte Quinolon-Carbonsäuren enthalten
US8906413B2 (en) 2003-05-12 2014-12-09 Supernus Pharmaceuticals, Inc. Drug formulations having reduced abuse potential
CA2531637A1 (fr) * 2003-07-23 2005-02-03 L. Perrigo Company Composition contenant des fibres cellulosiques
ES2515101T3 (es) 2004-06-04 2014-10-29 Debiopharm International Sa Derivados de acrilamida como agentes antibióticos
JP5046946B2 (ja) * 2004-10-15 2012-10-10 スパーナス ファーマシューティカルズ インコーポレイテッド 低乱用性薬学的製剤
KR20080075027A (ko) * 2005-12-05 2008-08-13 아피늄 파마슈티컬스, 인크. Fabi 억제제 및 항박테리아제로서의헤테로시클릴아크릴아미드 화합물
EP2054422B1 (fr) 2006-07-20 2017-06-14 Debiopharm International SA Dérivés d'acrylamide en tant qu'inhibiteurs de fab i
US8263613B2 (en) * 2007-02-16 2012-09-11 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab I inhibitors
NZ702695A (en) 2012-06-19 2015-10-30 Debiopharm Int Sa Prodrug derivatives of (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide
US10751351B2 (en) 2016-02-26 2020-08-25 Debiopharm International S.A. Medicament for treatment of diabetic foot infections

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3601566A1 (de) * 1986-01-21 1987-07-23 Bayer Ag Pharmazeutische zubereitungen von ciprofloxacin
US5286754A (en) 1986-01-21 1994-02-15 Bayer Aktiengesellschaft Pharmaceutical formulations of ciprofloxacin
US4957554A (en) 1989-08-16 1990-09-18 Minnesota Mining And Manufacturing Company Dimensionally-controlled ceramics
DE4120646A1 (de) 1991-06-22 1992-12-24 Bayer Ag 7-isoindolinyl-chinolon- und naphthyridoncarbonsaeure-derivate
NZ312199A (en) * 1995-08-29 1999-06-29 Pfizer Zwitterionic forms of trovafloxacin

Also Published As

Publication number Publication date
AP9901443A0 (en) 1999-03-31
KR100314977B1 (ko) 2001-11-24
SG70666A1 (en) 2000-02-22
HU9900154D0 (en) 1999-03-29
CN1227743A (zh) 1999-09-08
IS4947A (is) 1999-07-22
NZ333838A (en) 2000-03-27
DZ2712A1 (fr) 2003-09-01
OA10958A (en) 2001-10-31
EA199900046A2 (ru) 1999-08-26
AR012780A1 (es) 2000-11-08
HUP9900154A3 (en) 2000-12-28
TW518224B (en) 2003-01-21
EP0930068A2 (fr) 1999-07-21
BG103106A (en) 1999-08-31
BR9900116A (pt) 2000-05-02
CA2259698C (fr) 2003-04-15
AP1094A (en) 2002-08-19
ID23735A (id) 2000-05-11
TR199900089A3 (tr) 1999-10-21
HRP990023A2 (en) 1999-08-31
NO990243L (no) 1999-07-22
AU1217399A (en) 1999-08-12
HUP9900154A2 (hu) 1999-09-28
NO990243D0 (no) 1999-01-20
TNSN99007A1 (fr) 2005-11-10
PE20000169A1 (es) 2000-03-10
PA8466701A1 (es) 2000-09-29
GT199900004A (es) 2000-07-08
US6187341B1 (en) 2001-02-13
IL128051A0 (en) 1999-11-30
SK4299A3 (en) 2000-06-12
AU758381B2 (en) 2003-03-20
CO4810225A1 (es) 1999-06-30
EP0930068A3 (fr) 1999-12-22
PL330981A1 (en) 1999-08-02
EA199900046A3 (ru) 1999-12-29
JPH11269072A (ja) 1999-10-05
EA003247B1 (ru) 2003-02-27
CA2259698A1 (fr) 1999-07-21
TR199900089A2 (xx) 1999-10-21
ZA99393B (en) 2000-07-21
YU2399A (sh) 2002-06-19
KR19990068014A (ko) 1999-08-25

Similar Documents

Publication Publication Date Title
MA24747A1 (fr) Composition de mesylate de trovafloxacine et procede pour sa preparation
FR2795734B1 (fr) Conjugues d'erythropoietine,compositons les comprenant et procede pour leur preparation
MA25089A1 (fr) Formulations intranasales de mesylate de sildenafil et procede pour leur preparation
FR2791580B1 (fr) Procede pour l'enrobage de particules
FR2780057B1 (fr) Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
HUP0104582A3 (en) 1,2-annelated quinoline derivatives, pharmaceutical compositions thereof, intermediates and process for their preparation
FR2773807B1 (fr) Materiau cellulaire souple, composition et procede pour sa preparation
MA26630A1 (fr) 4-phenylpyperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA25984A1 (fr) Procede pour preparation de maleate d'amlodipine.
FR2780728B1 (fr) Sel de paroxetine nouveau, procede pour sa preparation et compositions pharmaceutiques le contenant
FR2752091B1 (fr) Composition pour electrode positive, procede de preparation
MA25223A1 (fr) Procede pour la preparation de 4-carboxy-amino-2-substitue-1,2,3,4 tetrahydroquinoleine
EE04739B1 (et) Tienüülasolüülalkoksüetaanamiinderivaadid, nende ja nende soolade valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ning vaheühend ja selle valmistamismeetod
EE03679B1 (et) Bensüüleetrite valmistamise protsess
EE200100574A (et) Uued ühendid, nende valmistamise meetod ning kasutamine
FR2781801B1 (fr) Procede pour la preparation de dianhydride pyromellique
MA24182A1 (fr) Procede pour la preparation de 2,4-diaminopyrimidines substituees
EE200000651A (et) Asoolid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon
FR2773558B1 (fr) Procede pour l'obtention de 1-butene
FI19992513A (fi) Menetelmä ja laite rullanvaihdossa
MA26710A1 (fr) Formulations de doramectine antiparasitaires et procede pour leur preparation
HUP0101326A3 (en) Paroxetine compositions and process for their preparation
HUP0104544A2 (en) New pharmaceutical composition and the process for its preparation
MA24834A1 (fr) Halogenures de phenoxyphenysulfonyle et procede pour leur preparation
MA26450A1 (fr) Dimesylate de cis-1-(3-ethoxyphenyl)-1-(4-phenyl-piperazine-1-yl)-4-methylcyclohexane, procede pour sa preparation et composition pharmaceutique.